Podchaser Logo
Home
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Released Monday, 25th March 2024
Good episode? Give it some love!
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Monday, 25th March 2024
Good episode? Give it some love!
Rate Episode

Unlock Episode Insights with

Podchaser Logo PRO

Reach • Demographics • Contacts • More

Pro Features

Audience & Reach for High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

See a breakdown of Audience & Reach for High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Unlock Episode Audience & Reach with Podchaser Pro

Brand Safety for High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

See Brand Safety for High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Unlock Episode Brand Safety with Podchaser Pro

Ad Rate Card of JAMA Neurology Author Interviews

How much does it cost to advertise on JAMA Neurology Author Interviews?

PlacementCost
Pre-rollAds played before an episode.
Mid-rollAds played during an episode.
Post-rollAds played after an episode.

Frequently Asked Questions about JAMA Neurology Author Interviews

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features